These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28576974)

  • 1. Lecithin:Cholesterol Acyltransferase Activation by Sulfhydryl-Reactive Small Molecules: Role of Cysteine-31.
    Freeman LA; Demosky SJ; Konaklieva M; Kuskovsky R; Aponte A; Ossoli AF; Gordon SM; Koby RF; Manthei KA; Shen M; Vaisman BL; Shamburek RD; Jadhav A; Calabresi L; Gucek M; Tesmer JJG; Levine RL; Remaley AT
    J Pharmacol Exp Ther; 2017 Aug; 362(2):306-318. PubMed ID: 28576974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol.
    Manthei KA; Yang SM; Baljinnyam B; Chang L; Glukhova A; Yuan W; Freeman LA; Maloney DJ; Schwendeman A; Remaley AT; Jadhav A; Tesmer JJ
    Elife; 2018 Nov; 7():. PubMed ID: 30479275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and functional analysis of missense mutations in the lecithin cholesterol acyltransferase gene in a Chilean patient with hypoalphalipoproteinemia.
    Tobar HE; Cataldo LR; González T; Rodríguez R; Serrano V; Arteaga A; Álvarez-Mercado A; Lagos CF; Vicuña L; Miranda JP; Pereira A; Bravo C; Aguilera CM; Eyheramendy S; Uauy R; Martínez Á; Gil Á; Francone O; Rigotti A; Santos JL
    Lipids Health Dis; 2019 Jun; 18(1):132. PubMed ID: 31164121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound.
    Pavanello C; Ossoli A; Turri M; Strazzella A; Simonelli S; Laurenzi T; Kono K; Yamada K; Kiyosawa N; Eberini I; Calabresi L
    J Pharmacol Exp Ther; 2020 Dec; 375(3):463-468. PubMed ID: 32980814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compound heterozygosity (G71R/R140H) in the lecithin:cholesterol acyltransferase (LCAT) gene results in an intermediate phenotype between LCAT-deficiency and fish-eye disease.
    Hörl G; Kroisel PM; Wagner E; Tiran B; Petek E; Steyrer E
    Atherosclerosis; 2006 Jul; 187(1):101-9. PubMed ID: 16216249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human plasma lecithin-cholesterol acyltransferase. The vicinal nature of cysteine 31 and cysteine 184 in the catalytic site.
    Jauhiainen M; Stevenson KJ; Dolphin PJ
    J Biol Chem; 1988 May; 263(14):6525-33. PubMed ID: 3129428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review on lecithin:cholesterol acyltransferase deficiency.
    Saeedi R; Li M; Frohlich J
    Clin Biochem; 2015 May; 48(7-8):472-5. PubMed ID: 25172171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial lecithin:cholesterol acyltransferase deficiency: molecular analysis of a compound heterozygote: LCAT (Arg147 --> Trp) and LCAT (Tyr171 --> Stop).
    Guerin M; Dachet C; Goulinet S; Chevet D; Dolphin PJ; Chapman MJ; Rouis M
    Atherosclerosis; 1997 May; 131(1):85-95. PubMed ID: 9180249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein subfractions highly associated with renal damage in familial lecithin:cholesterol acyltransferase deficiency.
    Kuroda M; Holleboom AG; Stroes ES; Asada S; Aoyagi Y; Kamata K; Yamashita S; Ishibashi S; Saito Y; Bujo H
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1756-62. PubMed ID: 24876348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency.
    Simonelli S; Tinti C; Salvini L; Tinti L; Ossoli A; Vitali C; Sousa V; Orsini G; Nolli ML; Franceschini G; Calabresi L
    Biologicals; 2013 Nov; 41(6):446-9. PubMed ID: 24140107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The P274S Mutation of Lecithin-Cholesterol Acyltransferase (LCAT) and Its Clinical Manifestations in a Large Kindred.
    Fountoulakis N; Lioudaki E; Lygerou D; Dermitzaki EK; Papakitsou I; Kounali V; Holleboom AG; Stratigis S; Belogianni C; Syngelaki P; Stratakis S; Evangeliou A; Gakiopoulou H; Kuivenhoven JA; Wevers R; Dafnis E; Stylianou K
    Am J Kidney Dis; 2019 Oct; 74(4):510-522. PubMed ID: 31103331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete and Partial Lecithin:Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis.
    Oldoni F; Baldassarre D; Castelnuovo S; Ossoli A; Amato M; van Capelleveen J; Hovingh GK; De Groot E; Bochem A; Simonelli S; Barbieri S; Veglia F; Franceschini G; Kuivenhoven JA; Holleboom AG; Calabresi L
    Circulation; 2018 Sep; 138(10):1000-1007. PubMed ID: 29748187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters.
    Chen Z; Wang SP; Krsmanovic ML; Castro-Perez J; Gagen K; Mendoza V; Rosa R; Shah V; He T; Stout SJ; Geoghagen NS; Lee SH; McLaren DG; Wang L; Roddy TP; Plump AS; Hubbard BK; Sinz CJ; Johns DG
    Metabolism; 2012 Apr; 61(4):470-81. PubMed ID: 22001333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinuria in early childhood due to familial LCAT deficiency caused by loss of a disulfide bond in lecithin:cholesterol acyl transferase.
    Holleboom AG; Kuivenhoven JA; van Olden CC; Peter J; Schimmel AW; Levels JH; Valentijn RM; Vos P; Defesche JC; Kastelein JJ; Hovingh GK; Stroes ES; Hollak CE
    Atherosclerosis; 2011 May; 216(1):161-5. PubMed ID: 21315357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement.
    Shamburek RD; Bakker-Arkema R; Auerbach BJ; Krause BR; Homan R; Amar MJ; Freeman LA; Remaley AT
    J Clin Lipidol; 2016; 10(2):356-67. PubMed ID: 27055967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel LCAT (Lecithin:Cholesterol Acyltransferase) Activator DS-8190a Prevents the Progression of Plaque Accumulation in Atherosclerosis Models.
    Sasaki M; Delawary M; Sakurai H; Kobayashi H; Nakao N; Tsuru H; Fukushima Y; Honzumi S; Moriyama S; Wada N; Kaneko T; Yamada K; Terasaka N; Kubota K
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):360-376. PubMed ID: 33086872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease.
    Funke H; von Eckardstein A; Pritchard PH; Hornby AE; Wiebusch H; Motti C; Hayden MR; Dachet C; Jacotot B; Gerdes U
    J Clin Invest; 1993 Feb; 91(2):677-83. PubMed ID: 8432868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmission of two novel mutations in a pedigree with familial lecithin:cholesterol acyltransferase deficiency: structure-function relationships and studies in a compound heterozygous proband.
    Argyropoulos G; Jenkins A; Klein RL; Lyons T; Wagenhorst B; St Armand J; Marcovina SM; Albers JJ; Pritchard PH; Garvey WT
    J Lipid Res; 1998 Sep; 39(9):1870-6. PubMed ID: 9741700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lecithin: cholesterol acyltransferase (LCAT)--the genetic analysis of familial LCAT deficiency and fish eye disease].
    Bujo H; Saito Y
    Nihon Rinsho; 1995 May; 53(5):1260-6. PubMed ID: 7602789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of natural mutations in lecithin:cholesterol acyltransferase on the enzyme structure and activity.
    Peelman F; Verschelde JL; Vanloo B; Ampe C; Labeur C; Tavernier J; Vandekerckhove J; Rosseneu M
    J Lipid Res; 1999 Jan; 40(1):59-69. PubMed ID: 9869650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.